BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 22294726)

  • 1. Calcium blockers decrease the bortezomib resistance in mantle cell lymphoma via manipulation of tissue transglutaminase activities.
    Jung HJ; Chen Z; Wang M; Fayad L; Romaguera J; Kwak LW; McCarty N
    Blood; 2012 Mar; 119(11):2568-78. PubMed ID: 22294726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Degrasyn potentiates the antitumor effects of bortezomib in mantle cell lymphoma cells in vitro and in vivo: therapeutic implications.
    Pham LV; Tamayo AT; Li C; Bornmann W; Priebe W; Ford RJ
    Mol Cancer Ther; 2010 Jul; 9(7):2026-36. PubMed ID: 20606045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma.
    Yang DT; Young KH; Kahl BS; Markovina S; Miyamoto S
    Mol Cancer; 2008 May; 7():40. PubMed ID: 18489772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effects of the phosphoinostitide-3'-kinase delta inhibitor, CAL-101, in combination with Bortezomib on mantle lymophma cells and exploration of its related mechanism].
    Qu F; Xia B; Li X; Guo S; Zhang L; Tian C; Yu Y; Zhang Y
    Zhonghua Zhong Liu Za Zhi; 2015 Jun; 37(6):412-7. PubMed ID: 26463142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bortezomib-resistant nuclear factor κB expression in stem-like cells in mantle cell lymphoma.
    Jung HJ; Chen Z; Fayad L; Wang M; Romaguera J; Kwak LW; McCarty N
    Exp Hematol; 2012 Feb; 40(2):107-18.e2. PubMed ID: 22024108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib.
    Dasmahapatra G; Patel H; Dent P; Fisher RI; Friedberg J; Grant S
    Br J Haematol; 2013 Apr; 161(1):43-56. PubMed ID: 23360303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic anticancer effects of arsenic trioxide with bortezomib in mantle cell lymphoma.
    Jung HJ; Chen Z; McCarty N
    Am J Hematol; 2012 Dec; 87(12):1057-64. PubMed ID: 22965904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of CAAT/enhancer binding protein homologous protein in panobinostat-mediated potentiation of bortezomib-induced lethal endoplasmic reticulum stress in mantle cell lymphoma cells.
    Rao R; Nalluri S; Fiskus W; Savoie A; Buckley KM; Ha K; Balusu R; Joshi A; Coothankandaswamy V; Tao J; Sotomayor E; Atadja P; Bhalla KN
    Clin Cancer Res; 2010 Oct; 16(19):4742-54. PubMed ID: 20647473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis.
    Pham LV; Tamayo AT; Yoshimura LC; Lo P; Ford RJ
    J Immunol; 2003 Jul; 171(1):88-95. PubMed ID: 12816986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib.
    Sun B; Shah B; Fiskus W; Qi J; Rajapakshe K; Coarfa C; Li L; Devaraj SG; Sharma S; Zhang L; Wang ML; Saenz DT; Krieger S; Bradner JE; Bhalla KN
    Blood; 2015 Sep; 126(13):1565-74. PubMed ID: 26254443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiproliferative and proapoptotic activity of GUT-70 mediated through potent inhibition of Hsp90 in mantle cell lymphoma.
    Jin L; Tabe Y; Kimura S; Zhou Y; Kuroda J; Asou H; Inaba T; Konopleva M; Andreeff M; Miida T
    Br J Cancer; 2011 Jan; 104(1):91-100. PubMed ID: 21139584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The therapeutic effects of rGel/BLyS fusion toxin in in vitro and in vivo models of mantle cell lymphoma.
    Lyu MA; Pham LV; Sung B; Tamayo AT; Ahn KS; Hittelman WN; Cheung LH; Marks JW; Cho MJ; Ford RJ; Aggarwal BB; Rosenblum MG
    Biochem Pharmacol; 2012 Aug; 84(4):451-8. PubMed ID: 22687624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance.
    Kim A; Seong KM; Kang HJ; Park S; Lee SS
    Oncotarget; 2015 Nov; 6(35):38225-38. PubMed ID: 26517678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. P276-00, a cyclin-dependent kinase inhibitor, modulates cell cycle and induces apoptosis in vitro and in vivo in mantle cell lymphoma cell lines.
    Shirsath NP; Manohar SM; Joshi KS
    Mol Cancer; 2012 Oct; 11():77. PubMed ID: 23075291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intracellular NAD⁺ depletion enhances bortezomib-induced anti-myeloma activity.
    Cagnetta A; Cea M; Calimeri T; Acharya C; Fulciniti M; Tai YT; Hideshima T; Chauhan D; Zhong MY; Patrone F; Nencioni A; Gobbi M; Richardson P; Munshi N; Anderson KC
    Blood; 2013 Aug; 122(7):1243-55. PubMed ID: 23823317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78.
    Roué G; Pérez-Galán P; Mozos A; López-Guerra M; Xargay-Torrent S; Rosich L; Saborit-Villarroya I; Normant E; Campo E; Colomer D
    Blood; 2011 Jan; 117(4):1270-9. PubMed ID: 21106982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of atiprimod and the proteasome inhibitor bortezomib induces apoptosis of mantle cell lymphoma in vitro and in vivo.
    Sun L; Zhang L; Qian J; Yang J; Yi Q; Dong W; Wang M
    Leuk Res; 2012 Mar; 36(3):363-8. PubMed ID: 22000823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Noxa mediates bortezomib induced apoptosis in both sensitive and intrinsically resistant mantle cell lymphoma cells and this effect is independent of constitutive activity of the AKT and NF-kappaB pathways.
    Rizzatti EG; Mora-Jensen H; Weniger MA; Gibellini F; Lee E; Daibata M; Lai R; Wiestner A
    Leuk Lymphoma; 2008 Apr; 49(4):798-808. PubMed ID: 18398749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
    Heider U; von Metzler I; Kaiser M; Rosche M; Sterz J; Rötzer S; Rademacher J; Jakob C; Fleissner C; Kuckelkorn U; Kloetzel PM; Sezer O
    Eur J Haematol; 2008 Feb; 80(2):133-42. PubMed ID: 18005386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TG2 and NF-κB Signaling Coordinates the Survival of Mantle Cell Lymphoma Cells via IL6-Mediated Autophagy.
    Zhang H; Chen Z; Miranda RN; Medeiros LJ; McCarty N
    Cancer Res; 2016 Nov; 76(21):6410-6423. PubMed ID: 27488529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.